Microneedle Patch Delivers Long-Acting Contraceptive
By HospiMedica International staff writers Posted on 31 Jan 2019 |
Image: Professor Mark Prausnitz holds an experimental microneedle contraceptive skin patch (Photo courtesy of Christopher Moore/Georgia Tech).
A new study shows how a long-acting contraceptive designed for self-administration could provide a new family planning option, particularly in developing nations.
Developed by researchers at the Georgia Institute of Technology (Georgia Tech; Atlanta, GA, USA) and the University of Michigan (U-M; Ann Arbor, USA), the novel patch is made of 100 microneedles molded from a blend of polylactic-co-glycolic acid (PLGA) and polylactic acid (PLA), two biodegradable polymers commonly used in sutures. Bubble structures situated in the patch backing allow the microneedles to penetrate skin under compression, and snap off under shear force within five seconds of patch administration.
The microneedles provide continuous, sustained release of the contraceptive hormone levonorgestrel. In a study in rats, the microneedle patch was well tolerated, leaving little visible evidence of use, and maintained plasma concentrations of the hormone above the human therapeutic level for one month. The researchers suggest that further development of the rapidly separable microneedle patch for self-administered, long-acting contraception could enable women to better control their fertility. The study was published on January 14, 2019, in Nature Biomedical Engineering.
“Our goal is for women to be able to self-administer long-acting contraceptives with the microneedle patch that would be applied to the skin for five seconds just once a month,” said corresponding author Professor Mark Prausnitz, PhD, of Georgia Tech. “We do not yet know how the contraceptive microneedle patches would work in humans. Because we are using a well-established contraceptive hormone, we are optimistic that the patch will be an effective contraceptive.”
Long-acting contraceptives are available in formats such as patches that must be worn continuously, intrauterine devices (IUDs) that must be placed by trained healthcare professionals, and drugs injected with hypodermic needles. If the microneedle contraceptive patch is ultimately approved for use, it could become the first self-administered, long-acting contraceptive that does not involve a conventional needle injection.
Related Links:
Georgia Institute of Technology
University of Michigan
Developed by researchers at the Georgia Institute of Technology (Georgia Tech; Atlanta, GA, USA) and the University of Michigan (U-M; Ann Arbor, USA), the novel patch is made of 100 microneedles molded from a blend of polylactic-co-glycolic acid (PLGA) and polylactic acid (PLA), two biodegradable polymers commonly used in sutures. Bubble structures situated in the patch backing allow the microneedles to penetrate skin under compression, and snap off under shear force within five seconds of patch administration.
The microneedles provide continuous, sustained release of the contraceptive hormone levonorgestrel. In a study in rats, the microneedle patch was well tolerated, leaving little visible evidence of use, and maintained plasma concentrations of the hormone above the human therapeutic level for one month. The researchers suggest that further development of the rapidly separable microneedle patch for self-administered, long-acting contraception could enable women to better control their fertility. The study was published on January 14, 2019, in Nature Biomedical Engineering.
“Our goal is for women to be able to self-administer long-acting contraceptives with the microneedle patch that would be applied to the skin for five seconds just once a month,” said corresponding author Professor Mark Prausnitz, PhD, of Georgia Tech. “We do not yet know how the contraceptive microneedle patches would work in humans. Because we are using a well-established contraceptive hormone, we are optimistic that the patch will be an effective contraceptive.”
Long-acting contraceptives are available in formats such as patches that must be worn continuously, intrauterine devices (IUDs) that must be placed by trained healthcare professionals, and drugs injected with hypodermic needles. If the microneedle contraceptive patch is ultimately approved for use, it could become the first self-administered, long-acting contraceptive that does not involve a conventional needle injection.
Related Links:
Georgia Institute of Technology
University of Michigan
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear